BETAMETHASONE DIPROPIONATE OINTMENT WITH CHINOFORM AND BETAMETHASONE VALERATE OINTMENT WITH CHINOFORM - A DOUBLE-BLIND COMPARISON IN SECONDARILY INFECTED DERMATOSESGIP L.1978; CURR. THERAPEUT. RES.; USA; DA. 1978; VOL. 24; NO 6; PP. 630-632; BIBL. 2 REF.Article

A NEW TOPICAL STEROID-ANTIBIOTIC COMBINATION, DIPROGENTAGIP L.1974; CURR. THERAPEUT. RES.; U.S.A.; DA. 1974; VOL. 16; NO 6; PP. 581-584; BIBL. 3REF.Article

A STUDY TO COMPARE THE EFFICACY OF HYDROCORTISONE 17-BUTYRATE (LOCOID REG.) 0.1% SCALE LOTION AND BETAMETHASONE 17-VALERATE (BETNOVATE REG.) 0.1% LOTION IN THE TREATMENT OF SEBORRHOEIC DERMATITIS OF THE SCALPGIP L.1979; CURR. THERAPEUT. RES.; USA; DA. 1979; VOL. 26; NO 5; PP. 607-610; BIBL. 10 REF.Article

HYDROCORTISONE 17-BUTYRATE 0,1% CREAM AND FLUOCINOLONE ACETONIDE 0,025% CREAM: A DOUBLE-BLIND COMPARISON IN PATIENTS SUFFERING FROM PSORIASIS OF THE SCALPGIP L.1981; CURR. THER. RES.; ISSN 0011-393X; USA; DA. 1981; VOL. 29; NO 1; PART. 2; PP. 198-201; BIBL. 12 REF.Article

CLINICAL RESULTS OBTAINED IN INFECTED STEROID-RESPONSIVE DERMATOSES USING A COMBINATION OF BETAMETHASONE DIPROPIONATE CREAM PLUS CHINOFORM.GIP L.1977; CURR. THERAPEUT. RES.; U.S.A.; DA. 1977; VOL. 22; NO 4; PP. 542-548; BIBL. 4 REF.Article

A DOUBLE-BLIND CLINICAL TRIAL OF DIPROLENE OINTMENT VERSUS DERMOVATE OINTMENT FOR RESISTANT PSORIASIS AND ATOPIC DERMATOSESGIP L; HAMFELT A.1981; CURR. THER. RES.; ISSN 0011-393X; USA; DA. 1981; VOL. 30; NO 6; PART 1; PP. 895-904; BIBL. 20 REF.Article

Comparison of oxiconazole (Ro13-8996) and econazole in dermatomycosesGIP, L.Mykosen. 1984, Vol 27, Num 6, pp 295-302, issn 0027-5557Article

The in vitro determination of lingering antimycotic effect of two 1% omoconazole-nitrate cream formulations following single tropical applicationGIP, L.Mycoses. 1988, Vol 31, Num 3, pp 155-158, issn 0933-7407Article

ERGEBNISSE EINES HALBSEITENVERGLEICHS ZWISCHEN TRAVOCORT^REG. CREME UND TRAVOGEN^REG. CREME BEI ENTZUENDLICHEN UND EKZEMATISIERTEN DERMATOMYKOSEN = ETUDE COMPARATIVE DE L'ACTION DES CREMES TRAVOCORT^REG. ET TRAVOGEN^REG. DANS LES DERMATOMYCOSES INFLAMMATOIRES ET ECZEMATEUSESGIP L; LANGEN ML.1980; MYKOSEN; DEU; DA. 1980; VOL. 23; NO 2; PP. 79-84; ABS. ENG; BIBL. 8 REF.Article

THE RAPIDITY OF THE EFFECT OF DIFFERENT TYPES OF TOPICOL CORTICOSTEROIDS: A DOUBLE-BLIND COMPARISON BETWEEN DIPRODERM OINTMENT 0.05PERCENT AND CALMURIL-HYDROCORTISONE 1PERCENT = RAPIDITE D'EFFET DE DIFFERENTS TYPES DE CORTICOSTEROIDES LOCAUX. COMPARAISON A DOUBLE INSU ENTRE LE DIPRODERME POMMADE A 0,15 ET LE CALMURIL-HYDROCORTISONE A 1%GIP L; KARLTORP N.1974; CURR. THERAPEUT. RES.; U.S.A.; DA. 1974; VOL. 16; NO 4; PP. 300-305; BIBL. 4REF.Article

INVESTIGATIONS OF A NEW SYNTHETIC STEROID, BETAMETHASONE-17, 21-DIPROPIONATE, IN ALCOHOLIC SOLUTION.FREDRIKSSON T; GIP L; HAMFELT A et al.1975; CURR. THERAPEUT. RES.; U.S.A.; DA. 1975; VOL. 18; NO 2; PP. 324-331; BIBL. 10 REF.Article

Hydrocortisone 17-butyrate 0.1 % lipocream versus betamethasone 17-valerate 0.1 % cream in the treatment of patients with dry severe chronic eczemaGIP, L; VERJANS, H. L.Current therapeutic research. 1987, Vol 41, Num 2, pp 258-264, issn 0011-393XArticle

A double-blind controlled trial of a new antipsoriatic cream containing urea and sodium chlorideGIP, L; LUNDBERG, M.Current therapeutic research. 1985, Vol 37, Num 4, pp 797-804, issn 0011-393XArticle

Black piedra : the first case treated with terbinafine (Lamisil®)GIP, L.British journal of dermatology. Supplement. 1994, Vol 130, Num 43, pp 26-28, issn 0366-077XConference Paper

Differential staining of fungi in clinical specimens using fluorescent whitening agent (Blankophor)GIP, L; ABELIN, J.Mykosen. 1987, Vol 30, Num 1, pp 21-24, issn 0027-5557Article

Hydrocortisone 17-butyrate 0.1% and chlorquinaldol 3% (locoid-C)® cream and betamethasone 17-valerate 0.1% and clioquinol 1% (celestona-C)® cream in the treatment of patients suffering from secondarily infected eczemaGIP, L; UNNA, P. J.Current therapeutic research. 1984, Vol 35, Num 5, pp 741-746, issn 0011-393XArticle

Dosisfindungsstudie zur Wirkstoffkonzentration (0,125%, 0,25% und 0,5%) in Amorolfin-Creme zur Behandlung von Dermatomykosen = A study about the concentration(0,125%, 0,25% and 0,5%) of Amorolfin cream in the treatment of cutaneous mycosesDEL PALACIO, A; GIP, L; BERGSTRÄSSER, M et al.H + G. Zeitschrift für Hautkrankheiten. Supplement. 1993, Vol 68, Num 1, pp 55-60, issn 0342-9687Article